Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News  >  Business Leaders  >  All news

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 
HomeAll newsMost read newsBusiness Leaders Biography 
Birthday : 08/11/1957
Place of birth : Tosu - Japan
Biography : Mr. Masayoshi Son is Chairman at Sprint Corp., Chairman at SoftBank Corp., Chairman at Yahoo Japan C
The feature you requested does not exist. However, we suggest the following feature:

Intrexon : Synthetic Biologics Reports that Data from the Phase 2 Trimesta(TM) Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator

11/25/2015 | 01:21pm US/Eastern

ROCKVILLE, Md., Nov. 25, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at the University of California, Los Angeles (UCLA) David Geffen School of Medicine, and the lead principal investigator of the Phase 2 clinical trial that evaluated Trimesta(TM) as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women, published additional clinical trial data in the journal, Lancet Neurology.


As previously disclosed in July 2015, Synthetic Biologics was informed by UCLA that magnetic resonance imaging (MRI) analyses were ongoing to evaluate changes in the brain that correlate with improvements seen in clinical outcomes. With the publication of the data by Dr. Voskuhl, the Company has received topline MRI data and UCLA's related analysis. Upon receipt of the MRI data set, as is typical with academic collaborations, Synthetic Biologics commenced a thorough third party analysis in order to confirm UCLA's results for potential business development discussions. The Company continues discussions with the neurology community and potential strategic partners, as it determines next steps for Trimesta.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON), a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the continued discussions with the neurology community and potential strategic partners and the intended potential of SYN-010 and SYN-004. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics' therapeutics, a failure of Synthetic Biologics' clinical trials, and those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure of Synthetic Biologics' clinical trials to receive anticipated funding, a failure of Synthetic Biologics' products for the prevention and treatment of diseases to be successfully developed or commercialized, Synthetic Biologics' inability to maintain its licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-reports-that-data-from-the-phase-2-trimesta-clinical-trial-for-relapsing-remitting-multiple-sclerosis-were-published-by-lead-principal-investigator-300184560.html

SOURCE Synthetic Biologics, Inc.

React to this article
Latest news about Masayoshi Son 
05/11 MASAYOSHI SON : Son says vice chairman Arora a strong future candidate to lead SoftBank
2014 MASAYOSHI SON : SoftBank Invests in Altaeros Energies'Buoyant Airborne Technology
2014 MASAYOSHI SON : SoftBank's first Sony smartphone deal takes aim at U.S. market
2014 MASAYOSHI SON : SoftBank's Son says new Sprint CEO a 'streetfighter', hints at price war
2014 MASAYOSHI SON : SoftBank to start selling personal robots next year
2013 MASAYOSHI SON : Third point has made no management proposals to SoftBank
2013 MASAYOSHI SON : SoftBank's Son buys Tokyo Tiffany building for $326 million -sources
2013 MASAYOSHI SON : Softbank CEO Son says 'very supportive' of Alibaba's partnership
2013 MASAYOSHI SON : Softbank on track to complete Sprint acquisition by July
2013 MASAYOSHI SON : SoftBank to meet Sprint investors, many eye higher bid
2013 MASAYOSHI SON : Ergen puts chips on Sprint in latest wireless bet
2012 MASAYOSHI SON : Raine Group arrives in big way as Softbank's adviser
1  2  3  4  5  6  7  8  9  10Next

Most Read News 
11/19 JACK DORSEY : Dorsey's Square jumps in market debut, offering hope to tech startups
11/20 STEVE JOBS : Laurene Powell Jobs backs Amplify education company bought from News Corp
11/19 DERMOT DESMOND : Ladbrokes resolute on Coral deal after criticism from shareholder Desmond
11/18 WILLIAM ACKMAN : Ackman's Pershing Square Holdings off 24.5 percent YTD
11/18DJHUGH GRANT : Top Stories Of The Day
11/20DJPETER NICHOLAS : Hillary Clinton to Propose Middle-Class Tax Cuts--Update
11/19DJRUPERT MURDOCH : Video Ads Like Facebook's 'Not Really Earning Anybody's Attention'
More news

Popular Business Leaders 
William Ackman Jean-michel Aulas Steve Ballmer Ernesto Bertarelli Luc Besson Vincent Bolloré Martin Bouygues Warren Buffett David Einhorn Albert Frère Bill Gates Philip Green Carl Icahn Steve Jobs Li Ka-shing Arnaud Lagardère Robert Louis-dreyfus Maurice Lévy Lakshmi Mittal Rupert Murdoch Xavier Niel Nelson Peltz Ferdinand Piëch Ted Rogers Johann Rupert Carlos Slim George Soros Ratan Tata Donald Trump Alain Weill
A-Z Business Leaders